Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 16;8(2):e000351. doi: 10.1136/jitc-2019-000351

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Various combinations between IDO1 inhibitor, anti-PD-1 antibody and radiation modulate the tumor microenvironment differently. (A) From KPC orthotopic implantation model mice, blood serum and tumor tissues were collected on day 9 and day 14. The normalized cell numbers of (B) CD4 +cells, (C) CD4 + PD-1 +cells, (D) CD8 +cells, (E) F4/80+CD11b+CD11 c negative cells, and (F) MHC-II +CD11c+cells as quantified by flow cytometry analysis in tumor-infiltrating cells. The cell numbers of immune cells per 1 million cells in the single cell suspensions of the tumors are shown in the histograms. Data represent mean±SEM of four mice per treatment group that was repeated twice. *P<0.05, **P<0.01; NS, not significant, by unpaired t-test and one-way ANOVA. ANOVA, analysis of variance; IDO1, indoleamine 2,3-dioxygenase 1; RT, radiation therapy.